CN1997663A - 不可分型的流感嗜血杆菌的多肽 - Google Patents

不可分型的流感嗜血杆菌的多肽 Download PDF

Info

Publication number
CN1997663A
CN1997663A CNA2005800238288A CN200580023828A CN1997663A CN 1997663 A CN1997663 A CN 1997663A CN A2005800238288 A CNA2005800238288 A CN A2005800238288A CN 200580023828 A CN200580023828 A CN 200580023828A CN 1997663 A CN1997663 A CN 1997663A
Authority
CN
China
Prior art keywords
cytoplasm
protein
polypeptide
seq
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800238288A
Other languages
English (en)
Chinese (zh)
Inventor
V·马斯格阿尼
M·阿科
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GSK Vaccines SRL
Original Assignee
Chiron SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron SRL filed Critical Chiron SRL
Publication of CN1997663A publication Critical patent/CN1997663A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CNA2005800238288A 2004-05-14 2005-05-16 不可分型的流感嗜血杆菌的多肽 Pending CN1997663A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0410866.8 2004-05-14
GBGB0410866.8A GB0410866D0 (en) 2004-05-14 2004-05-14 Haemophilius influenzae

Publications (1)

Publication Number Publication Date
CN1997663A true CN1997663A (zh) 2007-07-11

Family

ID=32527109

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800238288A Pending CN1997663A (zh) 2004-05-14 2005-05-16 不可分型的流感嗜血杆菌的多肽

Country Status (10)

Country Link
US (4) US7749518B2 (cg-RX-API-DMAC7.html)
EP (5) EP2351773A1 (cg-RX-API-DMAC7.html)
JP (2) JP2008506364A (cg-RX-API-DMAC7.html)
CN (1) CN1997663A (cg-RX-API-DMAC7.html)
BR (1) BRPI0511118A (cg-RX-API-DMAC7.html)
CA (1) CA2566632A1 (cg-RX-API-DMAC7.html)
GB (1) GB0410866D0 (cg-RX-API-DMAC7.html)
IN (1) IN2015KN00290A (cg-RX-API-DMAC7.html)
RU (1) RU2432357C2 (cg-RX-API-DMAC7.html)
WO (1) WO2005111066A2 (cg-RX-API-DMAC7.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103687613A (zh) * 2011-05-11 2014-03-26 里斯贝克保健瑞典股份公司 蛋白f-具有层粘连蛋白和玻连蛋白结合性能的新的流感嗜血杆菌粘附素
CN105555305A (zh) * 2013-04-24 2016-05-04 葛兰素史密丝克莱恩生物有限公司 用于生产膜抗原的一般化模块的突变体细菌
CN108671228A (zh) * 2012-04-26 2018-10-19 诺华股份有限公司 抗原和抗原组合
CN118388664A (zh) * 2024-05-21 2024-07-26 广东省农业科学院动物卫生研究所 副猪嗜血杆菌融合抗原及其应用

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE503837T1 (de) * 2000-02-28 2011-04-15 Novartis Vaccines & Diagnostic Hybride expression neisserscher proteine
ATE492288T1 (de) * 2002-10-11 2011-01-15 Novartis Vaccines & Diagnostic Polypeptidimpstoffe zum breiten schutz gegen hypervirulente meningokokken-linien
US8283114B2 (en) * 2003-03-06 2012-10-09 Nationwide Children's Hospital, Inc. Genes of an otitis media isolate of nontypeable Haemophilus influenzae
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
WO2006110413A2 (en) * 2005-03-30 2006-10-19 Novartis Vaccines And Diagnostics Inc. Haemophilus influenzae type b
JP5269594B2 (ja) 2005-08-10 2013-08-21 アルネ・フオシユグレン・アー・ベー モラクセラ・カタラーリスと上皮細胞、細胞外マトリックス蛋白質及び補体系の相互作用
ZA200805602B (en) * 2006-01-17 2009-12-30 Arne Forsgren A novel surface exposed haemophilus influenzae protein (protein E; pE)
US9132183B2 (en) * 2007-03-09 2015-09-15 Newport Laboratories Modified live (JMSO strain) Haemophilus parasuis vaccine
US8647642B2 (en) 2008-09-18 2014-02-11 Aviex Technologies, Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
AU2009329193A1 (en) * 2008-12-17 2011-07-14 Novartis Ag Meningococcal vaccines including hemoglobin receptor
US8617574B2 (en) * 2009-02-13 2013-12-31 Valneva Austria Gmbh Nontypable Haemophilus influenzae antigens
ITMI20090946A1 (it) 2009-05-28 2010-11-29 Novartis Ag Espressione di proteine ricombinanti
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
LT3243526T (lt) 2010-07-06 2020-02-10 Glaxosmithkline Biologicals S.A. Rnr pristatymas, skirtas keleto imuninio atsako paleidimui
US11291635B2 (en) 2010-07-06 2022-04-05 Glaxosmithkline Biological Sa Virion-like delivery particles for self-replicating RNA molecules
CA2804396C (en) 2010-07-06 2021-06-29 Novartis Ag Liposomes with lipids having an advantageous pka-value for rna delivery
HRP20160805T1 (hr) 2010-07-06 2016-08-12 Glaxosmithkline Biologicals Sa Imuniziranje velikih sisavaca malim dozama rna
SI3981427T1 (sl) 2010-08-31 2022-08-31 Glaxosmithkline Biologicals S.A. Pegilirani liposomi za dostavo imunogen-kodirajoče RNA
US20130189351A1 (en) 2010-08-31 2013-07-25 Novartis Ag Lipids suitable for liposomal delivery of protein coding rna
CN103269713B (zh) 2010-10-11 2016-01-20 诺华有限公司 抗原递送平台
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
BR112014000236A2 (pt) 2011-07-06 2017-02-14 Novartis Ag lipossomas com razão n:p útil para a liberação de moléculas de rna, composição e uso de ditos lipossomas
EP3854413A1 (en) 2011-07-06 2021-07-28 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
HUE041800T2 (hu) 2011-08-31 2019-05-28 Glaxosmithkline Biologicals Sa Pegilált liposzómák immunogént kódoló RNS bejuttatására
US9764027B2 (en) 2012-09-18 2017-09-19 Glaxosmithkline Biologicals Sa Outer membrane vesicles
KR102255108B1 (ko) 2013-03-08 2021-05-24 노파르티스 아게 활성제의 전달을 위한 지질 및 지질 조성물
US11274144B2 (en) 2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
US11248040B2 (en) 2013-09-26 2022-02-15 Trellis Bioscience, Llc Binding moieties for biofilm remediation
EP3083556B1 (en) 2013-12-19 2019-12-25 Novartis AG Lipids and lipid compositions for the delivery of active agents
EP4019506A1 (en) 2013-12-19 2022-06-29 Novartis AG Lipids and lipid compositions for the delivery of active agents
WO2016010840A1 (en) 2014-07-16 2016-01-21 Novartis Ag Method of encapsulating a nucleic acid in a lipid nanoparticle host
WO2016032342A1 (en) * 2014-08-27 2016-03-03 Switchfloat Holdings Limited An oil field tubular and an internal sleeve for use therewith, and a method of deactivating a float valve within the oil field tubular
ES2969956T3 (es) 2014-09-05 2024-05-23 Novartis Ag Lípidos y composiciones lipídicas para el suministro de agentes activos
EP3061826A1 (en) 2015-02-27 2016-08-31 Novartis AG Flavivirus replicons
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
EP3307307A4 (en) 2015-06-09 2019-05-01 The Board of Regents of the University of Oklahoma COMPOSITIONS AND TREATMENTS FOR HAEMOPHILUS INFLUENZAE
EP3322408B1 (en) 2015-07-14 2022-06-08 The Research Institute at Nationwide Children's Hospital Novel formulation for the elimination of cariogenic and opportunistic pathogens within the oral cavity
HK1255383A1 (zh) 2015-07-31 2019-08-16 The Research Institute At Nationwide Children's Hospital 去除生物膜的肽及抗體
WO2017066719A2 (en) 2015-10-14 2017-04-20 Research Institute At Nationwide Children's Hospital Hu specific interfering agents
KR20180135493A (ko) * 2016-04-27 2018-12-20 바이오셀즈(베이징) 바이오테크 코., 엘티디. 흥분성 신경독성 관련 손상의 치료 방법
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
JP7514621B2 (ja) 2017-01-04 2024-07-11 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル Ｄｎａｂｉｉワクチンおよび強化された活性を有する抗体
AU2018206560B9 (en) 2017-01-04 2025-04-03 Research Institute At Nationwide Children's Hospital Antibody fragments for the treatment of biofilm-related disorders
US20180221468A1 (en) * 2017-01-19 2018-08-09 Iowa State University Research Foundation, Inc. Haemophilus influenzae immunogen
US11746136B2 (en) 2017-03-15 2023-09-05 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
WO2020072993A1 (en) 2018-10-05 2020-04-09 Research Institute At Nationwide Children's Hospital Hmgb1 protein derivatives for the removal of biofilms cross-reference to related application
EP3931206A1 (en) * 2019-02-27 2022-01-05 Evaxion Biotech ApS Vaccines targeting h. influenzae
US12209118B2 (en) 2019-07-08 2025-01-28 Research Institute At Nationwide Children's Hospital Antibody compositions for disrupting biofilms
EP4110906A4 (en) * 2020-02-28 2024-03-20 Trait Biosciences, Inc. NOVEL SYSTEMS, METHODS AND COMPOSITIONS FOR THE GLYCOSYLATION OF CANNABINOID COMPOUNDS
US12116614B2 (en) 2020-06-30 2024-10-15 Research Institute At Nationwide Children's Hospital Methods for determining antibiotic sensitivity
MX2023004371A (es) 2020-10-14 2023-07-26 George Mason Res Foundation Inc Lípidos ionizables, y métodos de fabricación y uso de los mismos.
CN115678869B (zh) * 2021-07-28 2025-08-29 梅花(上海)生物科技有限公司 一株重组菌株及其生产氨基酸的方法
US20250134824A1 (en) 2021-08-16 2025-05-01 Glaxosmithkline Biologicals Sa Low-dose lyophilized rna vaccines and methods for preparing and using the same
EP4387597A1 (en) 2021-08-16 2024-06-26 GlaxoSmithKline Biologicals SA Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof
CN114574456B (zh) * 2022-03-18 2022-08-12 华南理工大学 一种亚硝酸盐还原酶突变体及其编码基因和应用
GB202303019D0 (en) 2023-03-01 2023-04-12 Glaxosmithkline Biologicals Sa Method of lyophilisation
CN116236575B (zh) * 2023-03-07 2025-03-25 北京化工大学 一种光控偶联型纳米探针及其制备方法、光控偶联的纳米颗粒组合物与应用
GB202311382D0 (en) 2023-07-25 2023-09-06 Glaxosmithkline Biologicals Sa Lyophilised compostion

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB234768A (en) * 1924-05-28 1925-08-27 Ritter Dental Mfg Company Inc Improvements in adjustable brackets for supporting head-rests or other articles
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230423A (en) 1988-08-25 1993-08-26 Liposome Co Inc A dosage form comprising an antigen and a multilamellar liposome comprising dimyristolyphosphatidylcholine (dmpc) and cholesterol
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
EP0482068A1 (en) 1989-07-14 1992-04-29 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
ATE128628T1 (de) 1990-08-13 1995-10-15 American Cyanamid Co Faser-hemagglutinin von bordetella pertussis als träger für konjugierten impfstoff.
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
EP0812593B8 (en) 1993-03-23 2010-11-10 SmithKline Beecham Biologicals S.A. Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
JPH09506247A (ja) * 1993-11-08 1997-06-24 コノート ラボラトリーズ リミテッド ヘモフィリス属菌株トランスフェリン受容体遺伝子
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6245337B1 (en) * 1994-08-25 2001-06-12 Washington University Haemophilus adherence and penetration proteins
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
US5707829A (en) 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
WO1998040100A1 (en) 1997-03-10 1998-09-17 Ottawa Civic Loeb Research Institute USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
EP1279401B1 (en) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
JP2002502882A (ja) 1998-02-12 2002-01-29 アメリカン・サイアナミド・カンパニー インターロイキン−１２とともに処方された肺炎球菌および髄膜炎菌のワクチン
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
TR200002930T2 (tr) 1998-04-09 2000-12-21 Smithkline Beecham Biologicals S.A. Kolaylaştırıcı kompozisyonlar
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
US7357936B1 (en) 1998-10-16 2008-04-15 Smithkline Beecham Biologicals, Sa Adjuvant systems and vaccines
EP1162999B1 (en) 1999-03-19 2006-11-29 Glaxosmithkline Biologicals S.A. Vaccine against Streptococcus pneumoniae
CA2365914A1 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
AU766635B2 (en) 1999-09-24 2003-10-23 Smithkline Beecham Biologicals (Sa) Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant
IL148672A0 (en) 1999-09-24 2002-09-12 Smithkline Beecham Biolog Use of combination of polyxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
AU3108001A (en) 2000-01-20 2001-12-24 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for inducing a th2 immune response
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
DE60132471T2 (de) 2000-09-26 2009-01-15 Idera Pharmaceuticals, Inc., Cambridge Modulation der immunostimulatorischen aktivität von immunostimulierenden oligonukleotidanaloga durch positionelle chemische veränderungen
EP2270171B1 (en) 2000-10-02 2013-09-04 ID Biomedical Corporation of Quebec Haemophilus influenzae antigens and corresponding DNA fragments
GB0026002D0 (en) * 2000-10-24 2000-12-13 Smithkline Beecham Biolog Novel compounds
EP1328543B1 (en) 2000-10-27 2009-08-12 Novartis Vaccines and Diagnostics S.r.l. Nucleic acids and proteins from streptococcus groups a & b
GB0109289D0 (en) * 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Novel compounds
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
CN100350972C (zh) 2001-07-26 2007-11-28 启龙股份公司 含有铝佐剂和组氨酸的疫苗
WO2003024480A2 (en) 2001-09-14 2003-03-27 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
AU2002339224B2 (en) 2001-09-14 2008-10-09 Kuros Us Llc Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
GB0200025D0 (en) * 2002-01-02 2002-02-13 Glaxosmithkline Biolog Sa Novel compounds
US20060068386A1 (en) * 2002-03-04 2006-03-30 Alexei Slesarev Complete genome and protein sequence of the hyperthermophile methanopyrus kandleri av19 and monophyly of archael methanogens and methods of use thereof
US8283114B2 (en) 2003-03-06 2012-10-09 Nationwide Children's Hospital, Inc. Genes of an otitis media isolate of nontypeable Haemophilus influenzae
EP1601688A2 (en) * 2003-03-06 2005-12-07 Children's Hospital, Inc. Genes of an otitis media isolate of nontypeable haemophilus influenzae
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
ZA200805602B (en) 2006-01-17 2009-12-30 Arne Forsgren A novel surface exposed haemophilus influenzae protein (protein E; pE)
AT507928B1 (de) 2008-06-30 2015-09-15 Coil Holding Gmbh Drosselspule für elektrische energieversorgungsnetze mit reduzierten schallemissionen
US9018858B2 (en) 2008-09-24 2015-04-28 B/E Aerospace, Inc. Calibration method for LED lighting systems

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103687613A (zh) * 2011-05-11 2014-03-26 里斯贝克保健瑞典股份公司 蛋白f-具有层粘连蛋白和玻连蛋白结合性能的新的流感嗜血杆菌粘附素
CN108671228A (zh) * 2012-04-26 2018-10-19 诺华股份有限公司 抗原和抗原组合
CN105555305A (zh) * 2013-04-24 2016-05-04 葛兰素史密丝克莱恩生物有限公司 用于生产膜抗原的一般化模块的突变体细菌
CN118388664A (zh) * 2024-05-21 2024-07-26 广东省农业科学院动物卫生研究所 副猪嗜血杆菌融合抗原及其应用

Also Published As

Publication number Publication date
EP2343313A1 (en) 2011-07-13
US9102729B2 (en) 2015-08-11
US20120148615A1 (en) 2012-06-14
EP1745067A2 (en) 2007-01-24
US8124098B2 (en) 2012-02-28
WO2005111066A3 (en) 2006-05-26
WO2005111066A8 (en) 2007-05-18
EP2341069A1 (en) 2011-07-06
JP2012000112A (ja) 2012-01-05
EP2351774A1 (en) 2011-08-03
IN2015KN00290A (cg-RX-API-DMAC7.html) 2015-06-12
RU2432357C2 (ru) 2011-10-27
US20100303822A1 (en) 2010-12-02
GB0410866D0 (en) 2004-06-16
CA2566632A1 (en) 2005-11-24
US20080267966A1 (en) 2008-10-30
US20140234363A1 (en) 2014-08-21
JP2008506364A (ja) 2008-03-06
BRPI0511118A (pt) 2007-11-27
EP2351773A1 (en) 2011-08-03
RU2006144093A (ru) 2008-06-20
WO2005111066A2 (en) 2005-11-24
US7749518B2 (en) 2010-07-06

Similar Documents

Publication Publication Date Title
US9102729B2 (en) Polypeptides from non-typeable Haemophilus influenzae
US20120093868A1 (en) Haemophilus influenzae type b
US10035826B2 (en) Proteins and nucleic acids from meningitis/sepsis-associated Escherichia coli
US8652773B2 (en) Genes of an otitis media isolate of nontypeable Haemophilus influenza
CN101203529A (zh) 来自脑膜炎/脓毒症相关性大肠杆菌的蛋白质和核酸
JP2008525033A (ja) Ｂ群連鎖球菌
AU2012207041A1 (en) Proteins and nucleic acids from meningitis/sepsis-associated Escherichia Coli
US11357845B2 (en) Protein antigens for vaccinating against nontypeable Haemophilus influenzae
HK1133019A (en) Genes of an otitis media isolate of nontypeable haemophilus influenzae
WO2001089454A2 (en) Proteus mirabilis-based vaccine

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CI02 Correction of invention patent application

Correction item: Large order list

Correct: You

Number: 28

Volume: 23

COR Change of bibliographic data

Free format text: CORRECT: LARGE SEQUENCE TABLE TO: BE

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20070711